Can Mounjaro Cause Breast Cancer?

Mounjaro is a dual GIP and GLP-1 receptor agonist, prescribed once weekly as a subcutaneous injection. When a new medicine is authorised, its safety profile is established through clinical trials and then monitored continuously as more people use it in the real world.

At the time of writing, breast cancer is not listed as a known side effect in Mounjaro's product information — it does not appear among the commonly, uncommonly, or rarely reported adverse reactions documented in the electronic Medicines Compendium (eMC) summary of product characteristics for tirzepatide. Regulatory bodies and manufacturers continue to monitor all prescription medicines for signals that may emerge over time, which is why Mounjaro carries a black triangle (▼) status in some countries, indicating it is subject to additional monitoring.

It is worth understanding that cancer concerns are not unique to Mounjaro — any medicine that is new to market receives this kind of scrutiny, and ongoing post-marketing surveillance is designed precisely to detect any signal that clinical trials may not have been large enough to identify.

Some people searching this question may have read about GLP-1 medicines and thyroid concerns (specifically thyroid C-cell tumours, which have been observed in animal studies with some GLP-1 receptor agonists). Breast tissue is separate from this, and no established causal link between tirzepatide and breast cancer has been identified in current product information. If you have concerns about thyroid-related effects or other cancer questions, these deserve a direct conversation with your prescriber — not something to manage on the basis of internet searching alone.

Questions about other unexpected symptoms sometimes come up alongside cancer concerns. If you are curious about other reported effects, you may find it useful to read about abdominal symptoms sometimes reported on Mounjaro, or explore the broader Mounjaro information hub for a fuller picture of what is and is not currently known about this medicine.

Living with any health question while on a new medicine can feel unsettling, and one of the most practical things you can do is keep a clear record of what you notice and when. This is where GLP Trackr's side-effect and symptom tracking becomes genuinely useful — you can log anything you observe, with dates and notes, creating a timeline you can bring to your prescriber rather than trying to recall details from memory at an appointment.

The app also generates a doctor report — a clear summary of your logged journey — which makes it easier to have informed conversations with your healthcare team about anything you are monitoring or concerned about. This is not a substitute for clinical assessment; it is a way to make the most of the time you have with your doctor.

If you are also tracking injection-site reactions such as bruising, or want to understand more about how Mounjaro relates to blood sugar and diabetes, GLP Trackr lets you log multiple types of observations in one place.

Any side effect that concerns you — whether or not it appears on the official list — should be reported to your healthcare professional. You can also report unexpected effects to your national pharmacovigilance scheme (such as the UK's Yellow Card scheme or its equivalent in your country), which helps regulators monitor medicine safety over time.

Always follow the guidance of your prescriber or doctor, who knows your full medical history. If you notice any new or unexplained physical changes while taking Mounjaro, do not wait — contact your healthcare professional promptly.

Want to keep a thorough record of your symptoms and health observations to share with your prescriber? Download GLP Trackr on the App Store or Google Play and explore it free for 7 days.